DK1090033T3 - Partikler af HCV-kappeproteiner: Anvendelse til vaccination - Google Patents

Partikler af HCV-kappeproteiner: Anvendelse til vaccination

Info

Publication number: DK1090033T3
Authority: DK; Denmark
Prior art keywords: hcv; vaccination; particles; proteins; envelope proteins
Prior art date: 1998-06-24

Application number

DK99929306T

Other languages

English (en)

Other versions

DK1090033T4 (da

Inventor

Erik Depla

Geert Maertens

Alfons Bosman

Wijnendaele Frans Van

Original Assignee

Innogenetics Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-24

Filing date

1999-06-23

Publication date

2005-04-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1090033(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-06-23 Application filed by Innogenetics Nv filed Critical Innogenetics Nv

2005-04-25 Publication of DK1090033T3 publication Critical patent/DK1090033T3/da

2008-03-31 Application granted granted Critical

2008-03-31 Publication of DK1090033T4 publication Critical patent/DK1090033T4/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK99929306T 1998-06-24 1999-06-23 Partikler af HCV-kappeproteiner: Anvendelse til vaccination DK1090033T4 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP98870142		1998-06-24
EP99870033		1999-02-22
PCT/EP1999/004342 WO1999067285A1 (en)	1998-06-24	1999-06-23	Particles of hcv envelope proteins: use for vaccination

Publications (2)

Publication Number	Publication Date
DK1090033T3 true DK1090033T3 (da)	2005-04-25
DK1090033T4 DK1090033T4 (da)	2008-03-31

Family

ID=26152268

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99929306T DK1090033T4 (da)	1998-06-24	1999-06-23	Partikler af HCV-kappeproteiner: Anvendelse til vaccination

Country Status (21)

Country	Link
US (3)	US6635257B1 (da)
EP (2)	EP1090033B2 (da)
JP (1)	JP2002518037A (da)
KR (1)	KR100559096B1 (da)
CN (1)	CN1313864A (da)
AT (1)	ATE286067T1 (da)
AU (1)	AU765940B2 (da)
BR (1)	BR9911397A (da)
CA (1)	CA2330526A1 (da)
DE (1)	DE69922958T3 (da)
DK (1)	DK1090033T4 (da)
ES (1)	ES2237115T5 (da)
HK (1)	HK1037639A1 (da)
HU (1)	HU227275B1 (da)
IL (2)	IL140217A0 (da)
NZ (2)	NZ528952A (da)
PL (1)	PL201679B1 (da)
PT (1)	PT1090033E (da)
RU (1)	RU2247729C2 (da)
TR (1)	TR200003843T2 (da)
WO (1)	WO1999067285A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040185061A1 (en) *	1994-07-29	2004-09-23	Innogenetics N.V.	Redox reversible HCV proteins with native-like conformation
US7108855B2 (en)	1998-06-24	2006-09-19	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
ATE286067T1 (de) *	1998-06-24	2005-01-15	Innogenetics Nv	Hcv hüllproteine partikel : verwendung für therapeutische impfung
US6534064B1 (en) *	1999-10-13	2003-03-18	Chiron Corporation	Stabilized protein particles for inducing cellular immune responses
WO2001093905A1 (en) *	2000-06-08	2001-12-13	Intercell Biomedizinische Forschungs- Und Entwicklungs Ag	Immunostimulatory oligodeoxynucleotides
EP1315511A4 (en) *	2000-09-08	2005-10-19	Gryphon Therapeutics Inc	SYNTHESIS PROTEINS STIMULATING ERYTHROPOYSIS
EP1326625A4 (en) *	2000-09-13	2005-05-04	Hawaii Biotech Inc	IMMUNOGENIC COMPOSITION OF HEPATITIS C AND METHODS OF USING THE SAME
US7101561B2 (en) *	2000-12-01	2006-09-05	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2002086101A2 (en)	2001-04-24	2002-10-31	Innogenetics N.V.	Core-glycosylated hcv envelope proteins
GB0114629D0 (en) *	2001-06-15	2001-08-08	Pfizer Ltd	Method
CN1622828A (zh) *	2001-12-18	2005-06-01	基因创新有限公司	用于诊断和治疗用途的纯化的丙型肝炎病毒外被蛋白
US20040126395A1 (en) *	2001-12-18	2004-07-01	Geert Maertens	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
FR2839722A1 (fr)	2002-05-17	2003-11-21	Bio Merieux	Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
JP2004085528A (ja) *	2002-07-05	2004-03-18	Kansai Tlo Kk	拡散定数変化による蛋白質の会合検出方法及び装置
EP1553963A4 (en) *	2002-09-24	2006-05-03	Burnham Inst	NEW MEANS FOR MODULATING EPH RECEPTOR ACTIVITY
EP1852441B1 (en) *	2002-09-24	2012-03-28	The Burnham Institute	Agents that modulate EPH receptor activity
EP1481985A1 (en) *	2003-05-28	2004-12-01	Innogenetics N.V.	Modified hepatitis C virus (HCV) NS3 for medical treatment
EP1561470A1 (en) *	2003-06-20	2005-08-10	Innogenetics N.V.	HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
CN1889963A (zh) *	2003-10-10	2007-01-03	宝德杰克特疫苗有限公司	方法
WO2006070028A1 (es) *	2004-12-23	2006-07-06	Berthet Francois Xavier	Composiciones y procedimientos para detectar infección patógena
GB0500020D0 (en)	2005-01-04	2005-02-09	Novartis Ag	Organic compounds
EP1574517A1 (en) *	2004-03-09	2005-09-14	Innogenetics N.V.	HCV E1 comprising specific disulfide bridges
WO2006033012A2 (en) *	2004-09-24	2006-03-30	Pfizer Limited	Method of screening for modulators of hepatitis c virus infection
DE102004057111A1 (de)	2004-11-26	2006-06-01	Niles-Simmons Industrieanlagen Gmbh	Verfahren zum Zwischenbearbeiten von Wellen
KR20070118230A (ko)	2005-01-27	2007-12-14	더 번햄 인스티튜트	Ｅｐｈｂ 수용체-결합 펩티드
WO2007041432A2 (en) *	2005-09-30	2007-04-12	Novartis Vaccines And Diagnostics, Inc.	Cross-neutralization of hcv with recombinant proteins
EP2004684A4 (en) *	2006-03-22	2009-05-06	Genimmune N V	THE HEPATITIS C-VIRUS NEUTRALIZING ANTIBODIES
CA2722423A1 (en) *	2008-04-22	2009-10-29	Rutgers, The State University	Hcv e2 construct compositions and methods
US9758794B2 (en)	2008-04-22	2017-09-12	Rutgers, The State University Of New Jersey	HCV E2 construct compositions and methods
WO2010052214A2 (en) *	2008-11-05	2010-05-14	Glaxosmithkline Biologicals S.A.	Novel method
BR112013032675A2 (pt) *	2011-06-19	2017-08-08	Vaxine Pty Ltd	composição adjuvante de vacina compreendendo partículas de inulina
JP6567824B2 (ja) *	2011-10-12	2019-08-28	ザトラスティーズオブザユニバーシティオブペンシルバニア	ヒトパピローマウイルスのワクチンおよびその使用方法
RU2510998C2 (ru) *	2012-08-01	2014-04-10	Николай Николаевич Грановский	ВАКЦИНА НА ОСНОВЕ ВИРУСОПОДОБНЫХ ЧАСТИЦ, СОДЕРЖАЩИХ ВСЕ СТРУКТУРНЫЕ АНТИГЕНЫ ВИРУСА ГЕПАТИТА С, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ В ДРОЖЖАХ Hansenula polymorpha
JP6517779B2 (ja)	2013-03-12	2019-05-22	ザトラスティーズオブザユニバーシティオブペンシルバニア	ヒトパピローマウイルスの改良型ワクチンおよびその使用方法
US11324818B2 (en)	2016-09-21	2022-05-10	The Governors Of The University Of Alberta	Hepatitis c virus immunogenic compositions and methods of use thereof
JP6795468B2 (ja) *	2017-07-14	2020-12-02	ザトラスティーズオブザユニバーシティオブペンシルバニア	ヒトパピローマウイルスのワクチンおよびその使用方法
JP7075130B2 (ja) *	2019-10-25	2022-05-25	ザトラスティーズオブザユニバーシティオブペンシルバニア	ヒトパピローマウイルスのワクチンおよびその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4395395A (en) *	1979-05-21	1983-07-26	The United States Of America As Represented By The Department Of Health And Human Services	Detection of non-A, non-B hepatitis associated antigen
US6274148B1 (en) *	1990-11-08	2001-08-14	Chiron Corporation	Hepatitis C virus asialoglycoproteins
EP0992580B1 (en) *	1993-11-04	2005-03-09	Innogenetics N.V.	Immunodominant human T-cell epitopes of Hepatitis C virus
SG71728A1 (en) *	1994-07-29	2000-04-18	Innogenetics Nv	Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AU702436B2 (en) *	1994-10-21	1999-02-18	Innogenetics N.V.	New sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
CA2269097C (en)	1996-11-08	2007-01-09	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Synthesis and purification of hepatitis c virus-like particles
EP1071955B2 (en) *	1998-04-17	2009-02-18	N.V. Innogenetics S.A.	Improved immunodiagnostic assays using reducing agents
ATE286067T1 (de) *	1998-06-24	2005-01-15	Innogenetics Nv	Hcv hüllproteine partikel : verwendung für therapeutische impfung

1999
- 1999-06-23 AT AT99929306T patent/ATE286067T1/de not_active IP Right Cessation
- 1999-06-23 DK DK99929306T patent/DK1090033T4/da active
- 1999-06-23 AU AU46152/99A patent/AU765940B2/en not_active Ceased
- 1999-06-23 HU HU0102478A patent/HU227275B1/hu not_active IP Right Cessation
- 1999-06-23 CA CA002330526A patent/CA2330526A1/en not_active Abandoned
- 1999-06-23 KR KR1020007014761A patent/KR100559096B1/ko not_active IP Right Cessation
- 1999-06-23 PL PL345018A patent/PL201679B1/pl unknown
- 1999-06-23 EP EP99929306A patent/EP1090033B2/en not_active Expired - Lifetime
- 1999-06-23 WO PCT/EP1999/004342 patent/WO1999067285A1/en active IP Right Grant
- 1999-06-23 TR TR2000/03843T patent/TR200003843T2/xx unknown
- 1999-06-23 BR BR9911397-0A patent/BR9911397A/pt not_active Application Discontinuation
- 1999-06-23 PT PT99929306T patent/PT1090033E/pt unknown
- 1999-06-23 CN CN99809890A patent/CN1313864A/zh active Pending
- 1999-06-23 US US09/355,040 patent/US6635257B1/en not_active Expired - Fee Related
- 1999-06-23 DE DE69922958T patent/DE69922958T3/de not_active Expired - Fee Related
- 1999-06-23 NZ NZ528952A patent/NZ528952A/en unknown
- 1999-06-23 IL IL14021799A patent/IL140217A0/xx unknown
- 1999-06-23 NZ NZ508797A patent/NZ508797A/xx unknown
- 1999-06-23 JP JP2000555936A patent/JP2002518037A/ja active Pending
- 1999-06-23 EP EP04103826A patent/EP1555270A1/en not_active Withdrawn
- 1999-06-23 ES ES99929306T patent/ES2237115T5/es not_active Expired - Lifetime
- 1999-06-23 RU RU2001101869/13A patent/RU2247729C2/ru not_active IP Right Cessation
2000
- 2000-12-11 IL IL140217A patent/IL140217A/en not_active IP Right Cessation
2001
- 2001-10-11 HK HK01107139A patent/HK1037639A1/xx not_active IP Right Cessation
2003
- 2003-04-16 US US10/414,219 patent/US20030202987A1/en not_active Abandoned
2006
- 2006-06-02 US US11/445,274 patent/US20060275323A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU4615299A (en)	2000-01-10
DE69922958T2 (de)	2006-03-30
JP2002518037A (ja)	2002-06-25
PT1090033E (pt)	2005-05-31
US20060275323A1 (en)	2006-12-07
PL201679B1 (pl)	2009-04-30
EP1090033B2 (en)	2007-12-19
EP1090033A1 (en)	2001-04-11
CA2330526A1 (en)	1999-12-29
ES2237115T3 (es)	2005-07-16
ES2237115T5 (es)	2008-05-16
DE69922958T3 (de)	2008-06-26
EP1090033B1 (en)	2004-12-29
AU765940B2 (en)	2003-10-02
HK1037639A1 (en)	2002-02-15
ATE286067T1 (de)	2005-01-15
KR100559096B1 (ko)	2006-03-15
TR200003843T2 (tr)	2001-06-21
HUP0102478A3 (en)	2004-10-28
NZ528952A (en)	2004-09-24
US20030202987A1 (en)	2003-10-30
HUP0102478A2 (hu)	2001-10-28
CN1313864A (zh)	2001-09-19
IL140217A0 (en)	2002-02-10
BR9911397A (pt)	2002-01-15
WO1999067285A1 (en)	1999-12-29
DE69922958D1 (de)	2005-02-03
PL345018A1 (en)	2001-11-19
IL140217A (en)	2009-09-22
HU227275B1 (en)	2011-01-28
NZ508797A (en)	2004-02-27
US6635257B1 (en)	2003-10-21
DK1090033T4 (da)	2008-03-31
KR20010053181A (ko)	2001-06-25
RU2247729C2 (ru)	2005-03-10
EP1555270A1 (en)	2005-07-20

Publication	Publication Date	Title
DK1090033T4 (da)	2008-03-31	Partikler af HCV-kappeproteiner: Anvendelse til vaccination
ATE404220T1 (de)	2008-08-15	Rekombinierte pockenvirus-tollwut zusammensetzung und kombinierte zusammensetzungen und deren verwendung
DE60121136D1 (de)	2006-08-10	Proteasom-influenzavirus-impfstoffzusammensetzung
BR9814487A (pt)	2000-10-10	"vacina"
DE58906121D1 (de)	1993-12-16	Rekombinantes Vaccinia-Virus MVA.
DK0587780T4 (da)	2008-10-13	Smitstof, som forårsager Mystery Swine Disease,vaccinepræparater og diagnostiske sæt
MA24638A1 (fr)	1999-04-01	Vaccin
ATE405647T1 (de)	2008-09-15	Rekombinantes gelatin in impstoffen
EE200200709A (et)	2004-08-16	Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
NO20001768L (no)	2000-06-02	Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
CA2505942A1 (en)	2004-06-03	West nile virus vaccine
AU2002220460A1 (en)	2002-05-27	The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
BR0312194A (pt)	2005-04-26	Vìrus mononegaviral recombinante, vìrus do sarampo recombinante, vetor de vìrus do sarampo recombinante, sistema de resgate, composição imunogênica e composição de vacina
BRPI0113155B8 (pt)	2019-08-13	métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
AU9215101A (en)	2002-02-25	Vaccines containing ribavirin and methods of use thereof
MXPA03006971A (es)	2004-05-05	Tratamiento del virus de hepatitis b.
EP1613345A4 (en)	2007-01-10	COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320
WO2000012535A3 (en)	2000-06-08	Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
WO2005011571A3 (en)	2006-01-05	Hepatitis virus core proteins as vaccine platforms and methods of use thereof
MXPA06013388A (es)	2007-06-19	Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
BR0112020A (pt)	2003-05-13	Partìculas tipo vìrus de bvdv
ATE425187T1 (de)	2009-03-15	Materialien und methoden zur behandlung von hepatitis c
DE69736779D1 (de)	2006-11-16	Zusammensetzungen von rekombinanten papillomavirus vakzinen
WO2004041853A3 (en)	2004-07-15	Hcv vaccine compositions comprising e1 and ns3 peptides
ATE381351T1 (de)	2008-01-15	Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten